Assenagon Asset Management S.A. Has $4.46 Million Position in Cencora, Inc. (NYSE:COR)

Assenagon Asset Management S.A. trimmed its position in Cencora, Inc. (NYSE:COR - Free Report) by 85.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 19,840 shares of the company's stock after selling 112,524 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Cencora were worth $4,458,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of COR. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Cencora by 26.3% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,809 shares of the company's stock worth $1,759,000 after acquiring an additional 1,626 shares during the period. Bridges Investment Management Inc. acquired a new stake in Cencora during the 2nd quarter valued at $318,000. AE Wealth Management LLC boosted its position in Cencora by 2.5% during the second quarter. AE Wealth Management LLC now owns 18,826 shares of the company's stock worth $4,242,000 after purchasing an additional 468 shares during the period. Sei Investments Co. increased its holdings in shares of Cencora by 2.5% in the second quarter. Sei Investments Co. now owns 275,154 shares of the company's stock valued at $61,994,000 after purchasing an additional 6,626 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its position in shares of Cencora by 176.9% in the second quarter. Thrivent Financial for Lutherans now owns 86,007 shares of the company's stock valued at $19,377,000 after purchasing an additional 54,949 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock valued at $17,790,912 over the last three months. 15.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on COR. Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Leerink Partners dropped their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Wells Fargo & Company decreased their price objective on Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a report on Friday, December 13th. Finally, Mizuho initiated coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus target price of $275.60.

Cencora Price Performance

COR traded up $3.16 on Tuesday, hitting $245.21. 1,207,258 shares of the stock were exchanged, compared to its average volume of 1,274,235. The firm has a market capitalization of $47.39 billion, a price-to-earnings ratio of 32.65, a PEG ratio of 1.51 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $253.27. The business has a 50-day moving average of $237.38 and a two-hundred day moving average of $234.15.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. This is a positive change from Cencora's previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora's dividend payout ratio (DPR) is currently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.